1.
Infect Dis Now
; 52(3): 181-182, 2022 05.
Article
in English
| MEDLINE
| ID: mdl-35172219
2.
J Hosp Infect
; 119: 189-191, 2022 01.
Article
in English
| MEDLINE
| ID: mdl-34800612
3.
Eur J Clin Microbiol Infect Dis
; 40(11): 2437-2442, 2021 Nov.
Article
in English
| MEDLINE
| ID: mdl-33907935
ABSTRACT
We conducted an observational retrospective study of all adults hospitalized for documented varicella-zoster virus (VZV) meningitis or encephalitis during years 2000-2015 in one referral centre. Thirty-six patients (21 males, 15 females) were included, with meningitis (n = 21), or meningoencephalitis (n = 15). Median age was 51 years [interquartile range, 35-76], and 6 patients (17%) were immunocompromised. Aciclovir was started in 32 patients (89%), with a median dose of 11 mg/kg/8 h [10-15]. No patient died, but 12 (33%) had neurological sequelae at discharge. Age was the only variable associated with adverse outcome (OR 1.98 [1.17-3.35] per 10-year increment, P = 0.011).
Subject(s)
Central Nervous System Infections/virology , Herpes Zoster/virology , Herpesvirus 3, Human/physiology , Acyclovir/therapeutic use , Adult , Aged , Antiviral Agents/therapeutic use , Central Nervous System Infections/drug therapy , Central Nervous System Infections/immunology , Female , Herpes Zoster/drug therapy , Herpes Zoster/immunology , Herpesvirus 3, Human/genetics , Herpesvirus 3, Human/isolation & purification , Humans , Immunocompromised Host , Male , Middle Aged , Retrospective Studies
4.
Med Mal Infect
; 50(1): 87-89, 2020 02.
Article
in English
| MEDLINE
| ID: mdl-31767157